About: Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Status: Delisted — removed_from_provider. This asset is no longer trading; historical data is shown.
MNMDNASDAQMind Medicine Inc
Mind Medicine Inc share price
MNMD price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
MNMD price performance
MNMD Market Signals